Introduction {#Sec1}
============

While the incidence of male breast cancer (MBC) in the general population is low (1:1000), it can be significantly elevated for patients with an underlying genetic predisposition. Comprehensive genetics evaluation of all MBC patients is important, as identification of various cancer-predisposing mutations can drastically impact medical management for patients and their family members. The *BRCA1* and *BRCA2* genes, implicated in hereditary breast and ovarian cancer syndrome (HBOC), have been associated with increased risks for MBC, and it is currently recommended that individuals with a personal or family history of male breast cancer undergo testing of these genes \[[@CR1]\]. *BRCA2* is the most frequently mutated gene in MBC cohorts, having been reported in 4--40% of MBC patients, depending on the population studied and the presence/absence of additional clinical history supporting a diagnosis of HBOC \[[@CR2]--[@CR9]\]. Cumulative lifetime breast cancer risks for male *BRCA1* and *BRCA2* pathogenic variant carriers are 1--2 and 5--10%, respectively. In addition to breast cancer, males with *BRCA1* or *BRCA2* pathogenic variants face increased lifetime risks for prostate and pancreatic cancers \[[@CR10]--[@CR12]\].

Beyond *BRCA1/BRCA2*, data are limited regarding genetic predisposition to MBC. Two independent studies have linked *CHEK2* 1100delC with MBC \[[@CR13], [@CR14]\]; however, results from multiple other studies have not confirmed this association \[[@CR15]--[@CR22]\]. Furthermore, the role of other *CHEK2* pathogenic variants in MBC is yet to be explored. Germline pathogenic variants in the *PTEN*, androgen receptor (*AR*), *NF1*, and *PALB2* genes have also been reported in MBC patients; however, associations with MBC have not been well-studied and risk estimates are not currently available \[[@CR23]--[@CR26]\].

The clinical availability of multi-gene panel testing (MGPT) presents an opportunity for patients to undergo comprehensive analysis of a wide range of cancer susceptibility genes, including those with and without established links to MBC. Despite increased utilization of such testing in hereditary cancer diagnostics, data remain limited regarding the yield of such testing for MBC patients. In a recent study of breast cancer patients who underwent MGPT, 31.8% (*n* = 7/22) of MBC cases tested positive for pathogenic or likely pathogenic variants: *BRCA1* (1)*, BRCA2* (3), *PALB2* (1), *CHEK2* (1), and *ATM* (1) \[[@CR8]\]. These results are yet to be validated in larger MBC cohorts. To better understand the genetic contribution to MBC and the yield of MGPT in this population, we retrospectively assessed a cohort of MBC patients referred for MGPT.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Clinical histories and molecular results were retrospectively reviewed for all MBC patients (*n* = 715) who underwent MGPT at Ambry Genetics between March 2012 and June 2016 (Aliso Viejo, CA). The following demographic and clinical history information was obtained from test requisition forms and clinic notes submitted by ordering providers: age at testing, ethnicity, *BRCA1/2* testing history, and personal/family cancer history. Patients were excluded if they were known *BRCA1/2* pathogenic variant carriers prior to MGPT (*n* = 1), if heterozygosity ratios of less than \<25% were observed for any reported alterations detected in the patient (*n* = 3), or if the only information suggesting a MBC diagnosis was an ICD-9 code (*n* = 3), leaving 708 MBC patients eligible for further study.

Laboratory methods {#Sec4}
------------------

Patients underwent comprehensive analysis of cancer susceptibility genes using a variety of gene panels (Online Resource 1). Genomic deoxyribonucleic acid (gDNA) was isolated from the patient's blood or saliva specimen using a standardized methodology (Qiagen, Valencia, CA) and quantified by spectrophotometer (Nanodrop; Thermoscientific, Pittsburgh, PA, or Infinite F200; Tecan, San Jose, CA). Sequence enrichment was performed by incorporating the gDNA onto a microfluidics chip or into microdroplets along with primer pairs or by a bait-capture methodology using long biotinylated oligonucleotide probes (Fluidigm, South San Francisco, CA, RainDance Technologies, Billerica, MA or Integrated DNA Technologies, San Diego, CA), followed by PCR and NGS analysis (Illumina, San Diego, CA) of all coding regions ± five bases into introns and untranslated regions (5′UTR and 3′UTR). Sanger sequencing was performed for any regions with insufficient depth of coverage for reliable heterozygous variant detection and for verification of variant calls, other than known non-pathogenic alterations. A targeted chromosomal microarray was used for the detection of gross deletions and duplications for each sample (Aglient, Santa Clara, CA). Initial data processing and base calling were performed with RTA 1.12.4 (HiSeq Control Software 1.4.5; Illumina). Sequence quality filtering was executed with CASAVA software (version 1.8.2; Illumina, Hayward, CA). Sequence fragments were aligned to the reference human genome (GRCh37), and variant calls were generated using CASAVA. A minimum quality threshold of Q20 was applied, translating to an accuracy of \>99.9% for the called bases.

Variant classification {#Sec5}
----------------------

Variants were annotated with the Ambry Variant Analyzer, a proprietary alignment and variant annotation software (Ambry Genetics) that assigned variants according to a five-tier variant classification protocol \[pathogenic mutation; variant, likely pathogenic (VLP); variant of unknown significance (VUS); variant, likely benign (VLB); and benign\], based on published recommendations from the American College of Medical Genetics and Genomics and the International Agency for Research on Cancer \[[@CR27]--[@CR29]\].

Statistical analysis {#Sec6}
--------------------

The frequency of pathogenic or likely pathogenic variants was calculated for *ATM*, *BARD1*, *BRCA1*, *BRCA2*, *BRIP1*, *CDH1*, *CHEK2*, *MRE11A*, *NBN*, *NF1*, *PALB2*, *PTEN*, *RAD50*, *RAD51C*, *RAD51D*, and *TP53*. To avoid potential bias introduced by prior *BRCA1/2* testing and the varying number of genes tested by panel type, the diagnostic yield of MGPT was assessed using MBC patients tested for all 16 breast cancer genes (*n* = 512) and then stratified by prior *BRCA1/2* testing status. Clinical history comparisons were performed using patients tested for all 16 breast cancer genes, after removal of cases with pathogenic variants in genes not associated with breast cancer (*n* = 6), multiple pathogenic variants in breast cancer genes (*n* = 5), patients with monoallelic *MUTYH* pathogenic variants as the only pathogenic variant detected (*n* = 5), and patients carrying the low-risk *CHEK2* p.I157T variant (*n* = 6). Multivariable logistic regression (controlling for age, ethnicity and panel ordered) was performed to compare personal history of additional primary cancers and family history of MBC. A two-sample *t* test was used to test the age difference between groups.

Breast cancer risk estimation {#Sec7}
-----------------------------

Among 708 MBC patients, 538 were Caucasian or Ashkenazi Jewish. Of these, individuals tested for all 16 breast cancer predisposition genes (*n* = 421) were subjected to breast cancer risk estimation. The non-Finn European population (NFE) in the Exome Aggregation Consortium (ExAC) dataset \[[@CR30]\], excluding The Cancer Genome Atlas (TCGA) exomes, were used as public controls for case--control association studies with Caucasian breast cancer cases, consistent with the effective use of this dataset for estimation of ovarian and prostate cancer risk in recent studies \[[@CR31], [@CR32]\]. ExAC filter PASS/non-PASS rather than PASS only variants from the ExAC NFE-non TCGA dataset were used because multiple pathogenic variants validated by Ambry Genetics were excluded from the filter PASS category of ExAC. Restricting to PASS only variants led to reduced numbers of variants in controls and inflated breast cancer risks associated with each gene. To account for low-quality ExAC variants, recurrent variants observed at significantly different frequencies in other populations or with sequence misalignment were excluded. All remaining loss of function variants (nonsense, frameshift, consensus dinucleotide splice site (±1 or 2), and any missense variants defined as pathogenic in ClinVar by clinical laboratories) in breast cancer cases and ExAC controls were selected for inclusion. A series of filtering steps were applied (Supplementary Methods) to normalize differences in the breast cancer cases and the ExAC controls. Breast cancer cases carrying two or more pathogenic variants were excluded because of potential for inflation of breast cancer risks. While this filter was not applied to ExAC data due to the absence of individual-level genotype data, these events are rare in the general population and should only have a minor, conservative impact on risks estimates. Similarly, large genomic rearrangements of one or more exons were excluded from cases and ExAC controls because rearrangements were not validated among controls. Sensitivity analyses were also conducted when restricting to cases without prior *BRCA1/2* testing, to account for ascertainment bias (*n* = 268). Associations with breast cancer were estimated using the Fisher's exact test.

Results {#Sec8}
=======

Demographics {#Sec9}
------------

This cohort was primarily Caucasian (66.1%), with other ethnicities each representing ≤10% of patients tested (Table [1](#Tab1){ref-type="table"}). Ethnicity was unspecified for 6.2% of the cohort. The majority of patients were aged 60 and older at the time of testing (71.7%) and at the time of first breast cancer diagnosis (61.0%). Four percent of MBC patients had a second primary breast cancer, and additional non-breast primary cancers were reported for 23.4%. The most common additional cancer was prostate cancer, which was significantly enriched in this cohort with a frequency of 9.5% (*n* = 67) compared with the general population (0.13%; *p* = 10^−16^) \[[@CR33]\]. A family history of MBC was reported for 6.4% of patients.Table 1Demographics of overall male breast cancer cohort (*n* = 708)Demographic*N*Total%Ethnicity Caucasian46870866.1 Ashkenazi Jewish707089.9 African American587088.2 Asian237083.2 Hispanic167082.3 Middle Eastern57080.7 Native American17080.1 Mixed ethnicity207082.8 Other37080.4 Unknown447086.2Panel ordered (total number of genes on panel) BRCAplus (5--6)11570816.2 GYNplus (9--13)77081.0 BRCAplus-expanded177082.4 BreastNext (14--18)29770841.9 OvaNext (19--24)667089.3 PancNext (range)57080.7 CancerNext (22--32)14870820.9 CancerNext-expanded (43--49)537087.5Age at testing 20--2927080.3 30--39187082.5 40--49437086.1 50--5913870819.5 60--6923470833.1 70--7918970826.7 80--897570810.6 90 and older97081.3Age at diagnosis^a^ 20--29106871.5 30--39286874.1 40--497068710.2 50--5916068723.3 60--6921068730.6 70--7915868723.0 80--89476876.8 90 and older46870.6Testing history Prior *BRCA1/2* testing22370831.5Clinical History^a^ Family history male breast cancer416436.4 Multiple primary breast cancers287064.0 Additional non-breast primary cancers16670823.4^a^Age at diagnosis and clinical history were not provided for all men in the cohort

Test results {#Sec10}
------------

Ninety-seven of 708 MBC patients were found to have at least one pathogenic or likely pathogenic variant in a breast cancer susceptibility gene (Table [2](#Tab2){ref-type="table"}). Seven of these patients were found to carry two pathogenic variants including one biallelic *ATM* carrier with a clinical diagnosis of ataxia-telangiectasia, two *ATM/BRCA2* carriers, one *BRIP1/BRCA2* carrier, one *BRCA1/CHEK2* carrier, one *BARD1/PALB2* carrier, and one *CHEK2/PALB2* carrier. *BRCA2* and *CHEK2* were the most frequently altered genes, with pathogenic variants identified in 11.0 and 4.1% of MBC patients with no prior *BRCA1/2* testing, respectively (Table [3](#Tab3){ref-type="table"}). No pathogenic variants were identified in the following hereditary breast cancer genes: *CDH1*, *PTEN*, *RAD50*, *RAD51C*, and *TP53*.Table 2Clinical histories of mutation carriers (N = 97)Positive gene(s)Pathogenic variant(s)First breast cancer ageBilateral/multiple breast cancersOther cancer(s)Family history of MBC^a^EthnicityNotes*ATM*p.K2756\*70--79NoLiver/melanoma/prostateNPCaucasian*ATM*p.R2832C60--69NoNoCaucasian*ATM*c.901+1G\>A70--79NoNoHispanic*ATM/ATM*c.5763-1050A\>G/c.8418+5_8418+8delGTGA50--59NoNoCaucasianAT clinical dx*ATM/BRCA2*p.W2638\*/c.5616_5620delAGTAA70--79NoProstateNoAfrican American*ATM/BRCA2*p.Q2651\*/p.Q548\*80--89NoSkinNoCaucasian*BARD1*p.Q564\*70--79NoNPCaucasian*BARD1/PALB2*c.1935_1954dup20/c.109-2A\>G50--59NoYesUnknown*BRCA1*EX11_13del50--59NoNoCaucasian*BRCA1*p.C61G60--69NoNoCaucasian*BRCA1*EX11_13del60--69NoNoCaucasian*BRCA1*c.5266dupC60--69NoNoCaucasian*BRCA1*c.3481_3491del1160--69NoLiverNoCaucasian*BRCA1/CHEK2*c.5177_5180delGAAA/c.1100delC40--49NoNoAfrican American*BRCA2*5′UTR_EX1del50--59NoBladderNPCaucasian*BRCA2*c.5576_5579delTTAA60--69NoNPCaucasian*BRCA2*c.9253dupA60--69NoNPAfrican American*BRCA2*p.R2520\*60--69YesNPMiddle Eastern*BRCA2*c.1813dupA70--79NoProstateNPCaucasian*BRCA2*5′UTR_EX1del60--69NoGastroesophagealNoCaucasian*BRCA2*c.518delG60--69NoLeukemiaNoAfrican American*BRCA2*c.1296_1297delGA60--69NoNoCaucasian*BRCA2*p.D2723H30--39NoNoCaucasian*BRCA2*c.7865dupA40--49NoBladderNoAsian*BRCA2*c.4456_4459delGTTA40--49YesNoAfrican American*BRCA2*c.3257_3258delTA40--49YesNoAfrican American*BRCA2*c.5164_5165delAG50--59NoNoAfrican American*BRCA2*c.5722_5723delCT50--59NoTonsil/NOSNoCaucasian*BRCA2*c.5946delT50--59NoUreterNoAshkenazi Jewish*BRCA2*5′UTR_EX15del50--59NoNoAshkenazi Jewish*BRCA2*c.8297delC50--59NoLymphomaNoCaucasian*BRCA2*c.8297delC50--59NoSkinNoCaucasian*BRCA2*c.8331+1G\>A50--59NoPancreas/melanomaNoCaucasian*BRCA2*p.E1953\*50--59NoNoCaucasian*BRCA2*c.6938-1G\>A50--59NoTonsilNoMixed ethnicity*BRCA2*c.5799_5802delCCAA60--69NoNoHispanic*BRCA2*c.5130_5133delTGTA60--69NoNoCaucasian*BRCA2*5′UTR_EX1del60--69NoNoCaucasian*BRCA2*c.6676_6677delGA60--69NoNoCaucasian*BRCA2*c.5722_5723delCT60--69NoProstateNoCaucasian*BRCA2*c.7977-1G\>C60--69NoYesCaucasian*BRCA2*c.6591_6592delTG60--69NoNoCaucasian*BRCA2*c.4940_4941delCA60--69NoNoMixed ethnicity*BRCA2*p.E1308\*60--69NoNoUnknown*BRCA2*c.1813dupA60--69NoNoCaucasian*BRCA2*c.5350_5351delAA60--69YesNoCaucasian*BRCA2*p.V159M60--69NoNoHispanic*BRCA2*c.9117G\>A60--69NoNoCaucasian*BRCA2*p.R2336P60--69NoNoOther*BRCA2*c.8374_8384del11insAGG60--69NoProstateNoCaucasian*BRCA2*p.R2520\*70--79NoProstateYesCaucasian*BRCA2*p.E3111\*70--79YesYesAfrican American*BRCA2*c.4876_4877delAA70--79YesColon/lymphomaNoCaucasian*BRCA2*c.778_779delGA70--79NoNoCaucasian*BRCA2*p.R2659K70--79NoProstateNoCaucasian*BRCA2*c.3975_3978dupTGCT70--79NoNoCaucasian*BRCA2*p.Q2859\*70--79NoNoCaucasian*BRCA2*p.E49\*70--79NoNoMixed ethnicity*BRCA2*c.9435_9436delGT70--79NoMelanoma/skinNoCaucasian*BRCA2*c.6068_6072delACCAG70--79NoBladderNoCaucasian*BRCA2*c.1929delG70--79NoMelanoma/skinNoCaucasian*BRCA2*c.3975_3978dupTGCT70--79NoColon/lungYesUnknown*BRCA2*p.Q3026\*90--99NoYesMixed ethnicity*BRCA2*p.R2520\*90--99NoNoCaucasian*BRCA2*c.5946delTNOSNoNoUnknown*BRCA2*c.4876_4877delAANOSYesNoHispanic*BRCA2/BRIP1*c.2808_2811delACAA/p.R798\*70--79NoYesCaucasian*CHEK2*c.591delA60--69NoNPCaucasian*CHEK2*p.R117G40--49NoNoCaucasian*CHEK2*c.1100delC40--49NoNoCaucasian*CHEK2*c.1100delC40--49NoNoCaucasian*CHEK2*c.1100delC40--49NoNoCaucasian*CHEK2*p.T476M50--59NoMelanomaNoUnknown*CHEK2*c.1100delC50--59NoKidneyNoCaucasian*CHEK2*p.I157T50--59NoNoCaucasian*CHEK2*p.T476M50--59NoColonNoCaucasian*CHEK2*p.I157T50--59NoNoCaucasian*CHEK2*c.1100delC50--59NoNoCaucasian*CHEK2*p.I157T50--59NoNoAshkenazi Jewish*CHEK2*c.1100delC60--69NoLeukemiaNoCaucasian*CHEK2*p.S428F60--69NoNoAshkenazi Jewish*CHEK2*c.1100delC60--69NoNoCaucasian*CHEK2*p.Q29\*70--79NoNoCaucasian*CHEK2*p.S428F70--79NoYesAshkenazi Jewish*CHEK2*p.I157T70--79NoNoCaucasian*CHEK2*p.I157T70--79NoNoCaucasian*CHEK2*c.1100delC\<59NoYesCaucasian*CHEK2/PALB2*p.I157T/c.172_175delTTGT70--79NoNoCaucasian*MRE11A*c.1867+2T\>C70--79NoNoCaucasian*NBN*c.657_661delACAAA70--79NoNoCaucasian*NF1*p.R1276\*50--59NoNPAfrican American*NF1*p.Q1070\*30--39NoNoAfrican AmericanNF1 clinical dx*NF1*c.1721+3A\>G40--49NoLeukemia/pheochromocytoma/lymphomaNoMixed ethnicitySon noted to have NF1 clinical dx*PALB2*c.661_662delinsTA50--59NoThyroidNoCaucasian*PALB2*p.Y1183\*50--59NoNoAshkenazi Jewish*PALB2*c.93dupA60--69NoNoCaucasian*RAD51D*c.270_271dupTA80--89NoNoAsian^a^ *NP* not provided Table 3Frequency of pathogenic variants in breast cancer genes in overall MBC cohort (*n* = 708)GeneNo prior *BRCA1/2* testingPrior *BRCA1/2* testingAll MBCTotal pathogenic/likely pathogenic variantsTotal tested^a^%Total pathogenic/likely pathogenic variantsTotal tested^a^%Total pathogenic/likely pathogenic variantsTotal tested^a^%*BRCA2*5348011.021971.0556778.1*CHEK2* (all)163864.161953.1225813.8*CHEK2* (excluding I157T)113862.851952.6165812.8*CHEK2* (I157T only)53861.311950.565811.0*ATM* ^b^63901.501960.065861.0*BRCA1*64801.301970.066770.9*NF1*23540.611580.635120.6*PALB2*24170.532041.556210.8*RAD51D*13540.301580.015120.2*BRIP1*13700.301940.015640.2*MRE11A*13700.301940.015640.2*NBN*13700.301940.015640.2*BARD1*03700.021941.025640.4^a^The total number of men tested varies by gene, as not all men were tested by the same panel of genes^b^ *ATM* biallelic individual was counted only once

Diagnostic yield {#Sec11}
----------------

To assess the diagnostic yield of MGPT for MBC patients, results were analyzed for patients tested for all 16 breast cancer genes (*n* = 512) (Table [4](#Tab4){ref-type="table"}). The overall mutation-positive rate for breast cancer susceptibility genes for patients with no prior *BRCA1/2* testing reported was 18.1% (*N* = 64/354), with 1.1% (*n* = 4) of patients carrying pathogenic variants in two different breast cancer genes. The overall mutation-positive rate for breast cancer susceptibility genes for patients with prior *BRCA1/2* testing reported was 7.6% (*N* = 12/158), with 1 patient carrying mutations in two different breast cancer genes. Of note, two patients in this group tested positive for *BRCA2* gross deletions that were not previously detected because gross deletion/duplication analysis had not been previously performed.Table 4Findings among MBC patients tested for 16 breast cancer genes (*n* = 512)Result categoryNo prior BRCA testing (*n* = 354)Prior BRCA testing (*n* = 158)*N*%*N*%Pathogenic/likely pathogenic variant6418.1127.6 Pathogenic/likely pathogenic variant(s) in a single gene60^a^16.9117.0  *BRCA1/2*3911.021.3  Non-*BRCA1/2*215.995.7 Pathogenic/likely pathogenic variant(s) in multiple genes41.110.6  Combination of *BRCA1/2* and non-*BRCA1/2* genes30.800.0  Multiple non-*BRCA1/2* genes10.310.6 Pathogenic/likely pathogenic variant + VUS164.553.2VUS only5916.73421.5Negative23165.311270.9^a^59 had a single pathogenic/likely pathogenic variant and 1 had biallelic *ATM* mutations

Clinical history comparisons {#Sec12}
----------------------------

The average age of diagnosis was similar for men with (63.5 ± 2.7 years) and without (62.3 ± 1.2 years; *p* = 0.43) pathogenic variants (Fig. [1](#Fig1){ref-type="fig"}). In addition, there was no significant difference in history of multiple primary cancers between patients with and without pathogenic variants (*p* = 0.13) (Fig. [2](#Fig2){ref-type="fig"}). However, patients with pathogenic variants were more likely to report multiple primary breast cancers (*p* = 4.16 × 10^−3^), with *BRCA2* accounting for all cases. There was no significant difference in family history of MBC (*p* = 0.37).Fig. 1Average age at breast cancer diagnosis based on test result Fig. 2Clinical histories of pathogenic carriers versus non-carriers

The average age of diagnosis for men with any *CHEK2* pathogenic variants (58.8 ± 6.4 years) was not significantly different from men with non-*CHEK2* pathogenic variants (64.6 ± 3.0 years; *p* = 0.09) or from men who did not test positive (62.3 ± 1.2 years; *p* = 0.26); however, *CHEK2* 1100delC carriers had a significantly lower average age of diagnosis (53.8 ± 9.6 years) compared to men with non-*CHEK2* variants (*p* = 0.03). No significant differences were observed between average age at breast cancer diagnosis for *CHEK2* 1100delC carriers compared to other *CHEK2* pathogenic variants (63.7 ± 9.6 years; *p* = 0.09) or to men who did not test positive (*p* = 0.07), though these trended toward significance.

Gene-specific risks of MBC {#Sec13}
--------------------------

Case--control analyses were performed based on sequencing results from 421 Caucasian MBC patients and 26,911 ExAC NFE-non TCGA controls. Pathogenic variants in *BRCA2* and *CHEK2* were significantly associated with increased risk of MBC (*BRCA2* OR = 13.9, *p* = 1.92 × 10^−16^; *CHEK2* OR = 2.43, *p* = 1.82 × 10^−3^) (Table [5](#Tab5){ref-type="table"}). Additional studies evaluating risks associated with *CHEK2* 1100delC and excluding common/low-risk missense variants (p.Ile157Thr and p.Ser428Phe) showed that truncating variants in *CHEK2* are associated with moderately increased risks of MBC (OR = 3.8; 95% CI 2.1--6.8; *p* = 1.51 × 10^−4^) (Table [5](#Tab5){ref-type="table"}). Variants in *PALB2* were also significantly associated with a high risk of MBC (OR = 6.6, *p* = 0.013) (Table [5](#Tab5){ref-type="table"}). However, this risk estimate is uncertain due to small numbers of MBCs with pathogenic variants (95% CI 1.70--21.09). Interestingly, few pathogenic variants were identified in *ATM* and *BRCA1*, which are commonly mutated in female familial breast cancer. No significant associations with MBC risks were observed. Sensitivity analyses excluding MBCs with prior testing of *BRCA1/2* showed very similar effects for pathogenic variants in these genes (Online Resource 3).Table 5Breast cancer risks associated with pathogenic variants pooled by gene among Caucasian male breast cancer casesGeneAmbry casesExAC controlsCancer riskMutated allelesCasesMutated allelesCasesOR95% CI lower95% CI upper*p* value*ATM*24219026,6441.40.35.10.66*BRCA1*23947426,9111.80.36.80.30*BRCA2*2139410526,79113.98.522.51.92 × 10^−16^*CHEK2* All1742142425,2152.41.43.91.82 × 10^−3^*CHEK2*\_c.1100delC842112725,2153.81.77.81.82 × 10^−3^*CHEK2* W/O I157T/S428F1042116325,2153.71.97.06.24 × 10^−4^*CHEK2* W/O I157T1242119125,2153.82.16.81.51 × 10^−4^*CHEK2* I157T542123325,2151.30.53.00.60*PALB2*34212926,8696.61.721.10.013

Discussion {#Sec14}
==========

Previously reported cohorts of MBC patients undergoing MGPT have included 22--51 cases \[[@CR8], [@CR9]\], making this the largest reported collection to date of MBC patients undergoing MGPT. As expected, *BRCA2* accounted for the largest percentage of pathogenic variants, whereas the observed frequency of *CHEK2* pathogenic variants (4.1%) was greater than expected based on previous reports of MBC in *CHEK2* cohorts. These findings support recent reports of the *CHEK2* pathogenic variant frequencies among MBC cases in the MGPT setting (4.5--7.8%) \[[@CR8], [@CR9]\]. While *BRCA2* is an established MBC susceptibility gene, literature regarding an association of *CHEK2* with MBC is conflicting. Despite an initial report in 2002 concluding that *CHEK2* 1100delC is associated with a tenfold risk for MBC \[[@CR13]\], and a subsequent report of an association between 1100delC and MBC in the Dutch population \[[@CR14]\], multiple other studies have not affirmed this association \[[@CR15]--[@CR22]\]. The limited number of probands affected with MBC (i.e., under 100 in most studies) and the lack of full sequencing of *CHEK2* in published cohorts may explain these conflicting reports. In the current study, *CHEK2* protein-truncating variants were associated with a 3.8-fold increased risk for MBC, which is highly consistent with findings from the studies of breast cancer families. Confidence intervals ranged from 2.1 to 6.8 suggesting that *CHEK2* is a moderate risk gene for MBC. In contrast, *BRCA2* pathogenic variants were associated with much higher risks of MBC (OR = 13.9; 95% CI 8.5--22.5).

Multiple *ATM* and *PALB2* pathogenic variants were also detected among MBC patients in this cohort. To our knowledge, this is only the second report of MBC in *ATM* heterozygotes \[[@CR8]\] and the first report of MBC in a patient with ataxia-telangiectasia. Of note, two of the five *ATM* pathogenic variant carriers in the refined 16-gene subgroup were multiple pathogenic variant carriers, including one *ATM* biallelic carrier and one *ATM/BRCA2* carrier. In the larger cohort, there was also one additional *ATM/BRCA2* carrier. Furthermore, *ATM* pathogenic variants were not significantly associated with MBC (Table [5](#Tab5){ref-type="table"}). These observations suggest *ATM* may act as an MBC risk modifier. There are multiple previous reports of *PALB2* pathogenic variants among MBC families, with a frequency ranging from 0.8 to 6.4%, although most reports have not met statistical significance \[[@CR23], [@CR34]--[@CR37]\]. One study reported that *PALB2* pathogenic variant carriers were four times more likely than *PALB2*-negative patients to have a relative with MBC (*p* \< 0.001) \[[@CR34]\]. In addition, Antoniou et al. reported an eightfold increased risk for MBC in *PALB2* carriers from moderate- and high-risk families; however, this did not reach statistical significance (*p* = 0.08) \[[@CR35]\]. Consistent with both reports, *PALB2* pathogenic variants in the current study were associated with a 6.6-fold increased risk of MBC (Table [5](#Tab5){ref-type="table"}). Further association studies, in families and in the general population, are needed to confirm the association of genes such as *ATM* and *PALB2* with MBC and to calculate more precise breast cancer risks for males with pathogenic variants in these genes.

Five (1.41%) of the MBC patients in the refined subgroup with no prior *BRCA* testing carried multiple pathogenic variants. As mentioned above, one of the MBC patients had biallelic *ATM* pathogenic variants and was noted to have a clinical history of ataxia-telangiectasia on the requisition form. Three of the multiple pathogenic variant carriers had a combination of pathogenic variants in one high-risk gene and one moderate risk gene: *BRCA1/CHEK2*, *BRCA2/ATM*, and *BRCA2/BRIP1*. The other multiple pathogenic variant carriers had mutations in two moderate-risk genes: *CHEK2/PALB2*. Excluding skin cancer, only the *BRCA2/ATM* pathogenic variant carrier reported multiple primary cancers (MBC and prostate cancer). The percentage of multiple pathogenic variants in this cohort and other reported MBC cohorts appears to be similar to multiple pathogenic variants in female breast cancer cohorts \[[@CR8], [@CR9]\].

Due to the relatively low number of pathogenic variants in other non-breast cancer genes in this cohort, it is difficult to assess whether MBC is an unrecognized component of the cancer spectra for these genes. Interestingly, several men tested positive for a pathogenic variant in genes associated with a syndromic presentation, including *APC* and *SDHA.* These patients did not have classical presentation of the associated syndromic features, indicating that gene-specific testing likely would not have been considered (Online Resource 2). Breast cancer---male or female---is not currently considered a component of the cancer spectra for these genes. While identification of a pathogenic variant in these cases is likely to impact medical management for other cancers, the result offers little insight into the most appropriate management of MBC risk, specifically, or whether other males in the family should be considered for testing and/or high-risk breast cancer screening.

No *PTEN* pathogenic variants were detected among MBC probands, despite previous reports of *PTEN* carriers with MBC. Since *PTEN* pathogenic variants are typically associated with Cowden syndrome (i.e., the presence of macrocephaly and characteristic mucocutaneous features in addition to cancer predisposition), it is likely that MBC patients with clinical histories suggestive of Cowden syndrome would be referred for *PTEN* testing alone rather than MGPT. Therefore, the absence of *PTEN* mutations in this cohort does not necessarily contradict previous reports. Similarly, pathogenic variants were not identified in *TP53* or *CDH1* in this cohort. While male breast cancer is not a major feature associated with either of these genes, it is possible that men with clinical histories suggestive of Li--Fraumeni syndrome or Hereditary Diffuse Gastric Cancer syndrome would have had single gene testing instead of MGPT, potentially introducing ascertainment bias with respect to these genes.

With the exception of men with *CHEK2* 1100delC, age of diagnosis was not predictive of positive test results. Although the number of men carrying the *CHEK2* 1100delC in this cohort is small, the significantly younger age of diagnosis in this subset may indicate that men with this specific pathogenic variant may warrant surveillance and/or a higher index of suspicion for male breast cancer at a younger age compared to men with other pathogenic variants. Family history of MBC and additional primary cancer diagnoses were also not predictive of positive results in this cohort, consistent with current NCCN *BRCA1/2* testing guidelines which recommend testing for MBC patients regardless of age at diagnosis or other clinical history. In contrast, multiple breast primary cancers were only identified in *BRCA2* pathogenic variant carriers in this cohort, suggesting a role for first-line *BRCA1/BRCA2* testing in men with this presentation.

The identification of pathogenic variants in MBC patients may have clinical implications both for the affected men and their relatives. For example, breast cancer screening is recommended for *BRCA1/BRCA2*-positive men, beginning at age 35, and increased colon surveillance is recommended for *CHEK2*-positive individuals \[[@CR1]\]. Several of the pathogenic variants identified in this cohort are associated with risks for other cancers, and their identification allows for increased surveillance which may lead to earlier detection of subsequent cancers. Many of the pathogenic variants identified in this cohort also carry significant risks for breast and ovarian cancer in women. Therefore, identification of variants in MBC patients allows for testing at-risk family members and increased surveillance and/or risk-reducing surgeries for positive relatives. Given the clinical implications for patients and their families, there appears to be utility in choosing a MGPT approach for MBC patients.

There are several limitations to this study. While previous *BRCA1/2* testing was controlled for in this analysis, it is possible that previous *BRCA1/2* testing was underreported in this group. Clinical history was ascertained by information reported on test requisition forms, and were verified by pedigree review when provided. As such, the analysis of secondary cancers and family history of cancer may be limited by the accuracy and completeness of the data provided. However, results from a recent study demonstrated that clinical history on test requisition forms at Ambry Genetics is highly accurate and complete for probands and highly accurate for relatives, with completeness correlating with relationship to the proband (i.e., more complete for first- and second-degree relatives and less complete for third-degree relatives and beyond) \[[@CR38]\]. In addition, as this is a retrospective review of men selected for different clinical genetic tests and may over-represent male breast cancer cases in the setting of a family history also indicative of a hereditary predisposition for cancer, the results of the study may be influenced by ascertainment bias or be specifically applicable to a high-risk population. Finally, segregation data in families with multiple cases of male breast cancer and in families with multiple pathogenic variants from this cohort are not available. Segregation data could potentially clarify the association between male breast cancer and the identified pathogenic variants in these families.

Results from this study build upon the current understanding of hereditary susceptibility to MBC. These data lend support to a MGPT approach for MBC patients regardless of age at diagnosis, history of multiple primary cancers, and family history of MBC. Furthermore, these data support *CHEK2* as a MBC susceptibility gene. The observed pathogenic variant frequency in this MBC cohort highlights the immediate need for studies investigating the most appropriate screening and risk management tools for MBC patients, particularly in cases with pathogenic variants in genes beyond *BRCA1/2*.
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